FIGURE 4.

Number of detected genetic mutations in AML patients. (A) Detection of genetic mutations that affect treatment decisions. Actionable mutations include FLT3‐ITD/TKD, IDH2 ^{R140Q/W,R172K}, IDH1 ^R132, and DNMT3A ^R882C/H mutation. Overall, 38% (n = 69) of the cases possessed usable genetic alteration for selecting treatment options. (B) Distribution of therapeutic target genes in the analyzed cohort. Gene mutations that can be used to determine treatment include FLT3‐ITD/TKD, IDH2 ^{R140Q/W,R172K}, IDH1 ^R132, and DNMT3A ^R882C/H mutation. Candidate gene mutations for clinical trials include mutation of TP53, KIT ^D816 , KRAS ^G12C , NPM1, and KMT2A rearrangements